These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17472572)

  • 1. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb.
    Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
    Biochem J; 2007 Sep; 406(2):237-46. PubMed ID: 17472572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha.
    Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
    Biotechnol Appl Biochem; 2008 Aug; 50(Pt 4):173-9. PubMed ID: 18047471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel human scFv fragment against TNF-alpha from de novo design method.
    Chang H; Qin W; Li Y; Zhang J; Lin Z; Lv M; Sun Y; Feng J; Shen B
    Mol Immunol; 2007 Jul; 44(15):3789-96. PubMed ID: 17485112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
    Coppieters K; Dreier T; Silence K; de Haard H; Lauwereys M; Casteels P; Beirnaert E; Jonckheere H; Van de Wiele C; Staelens L; Hostens J; Revets H; Remaut E; Elewaut D; Rottiers P
    Arthritis Rheum; 2006 Jun; 54(6):1856-66. PubMed ID: 16736523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha.
    Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
    Biotechnol Appl Biochem; 2006 Mar; 43(Pt 3):137-45. PubMed ID: 16293104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis.
    Qi J; Kan F; Ye X; Guo M; Zhang Y; Ren G; Li D
    Int Immunopharmacol; 2012 Dec; 14(4):770-8. PubMed ID: 23092552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression, effective renaturation, and bioactivity of novel single-chain antibodies against TNF-alpha.
    Geng S; Chang H; Qin W; Li Y; Feng J; Shen B
    Prep Biochem Biotechnol; 2008; 38(1):74-86. PubMed ID: 18080912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel bispecific antibody targeting tumor necrosis factor α and ED-B fibronectin effectively inhibits the progression of established collagen-induce arthritis.
    Liu M; Xie M; Jiang S; Liu G; Li L; Liu D; Yang X
    J Biotechnol; 2014 Sep; 186():1-12. PubMed ID: 24992210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis.
    Smith R; Tarner IH; Hollenhorst M; Lin C; Levicnik AU; Fathman CG; Nolan GP
    Gene Ther; 2003 Aug; 10(15):1248-57. PubMed ID: 12858190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.
    Piguet PF; Grau GE; Vesin C; Loetscher H; Gentz R; Lesslauer W
    Immunology; 1992 Dec; 77(4):510-4. PubMed ID: 1337334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
    Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
    Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
    Feldmann M; Brennan FM; Williams RO; Elliott MJ; Maini RN
    J Inflamm; 1995-1996; 47(1-2):90-6. PubMed ID: 8913935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstream characterization of anti-TNF-α single chain variable fragment antibodies.
    Abdolalizadeh J; Nouri M; Zolbanin JM; Baradaran B; Barzegari A; Omidi Y
    Hum Antibodies; 2012; 21(1-2):41-8. PubMed ID: 22885959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis.
    Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Mar; 43(3):638-44. PubMed ID: 10728758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
    Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M
    Arthritis Rheum; 2001 May; 44(5):1215-24. PubMed ID: 11352257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.